Dulaglutide : interactions médicamenteuses

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (notice Chloroquine, Mises en garde)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (notice Ciprofloxacine, Interactions médicamenteuses)

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (notice Fluconazole, Interactions médicamenteuses)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (notice Glipizide et metformine, Contre-indications)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (notice Hydroxychloroquine, Mises en garde et précautions)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (notice Dulaglutide, Mise en garde encadrée)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (notice Abiratérone, Mises en garde et précautions)

Consideration should be taken in patients being treated with antidiabetic agents. (notice Acétazolamide, Interactions médicamenteuses)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (notice Acitrétine, Interactions médicamenteuses)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (notice Amlodipine et bénazépril, Interactions médicamenteuses)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (notice Aspirine et dipyridamole, Interactions médicamenteuses)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (notice Atazanavir, Mises en garde et précautions)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (notice Bénazépril, Interactions médicamenteuses)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (notice Bénazépril et hydrochlorothiazide, Interactions médicamenteuses)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (notice Bexagliflozine, Interactions médicamenteuses)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (notice Bisoprolol, Mises en garde)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (notice Bisoprolol et hydrochlorothiazide, Précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Brimonidine et timolol, Mises en garde et précautions)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (notice Butalbital, aspirine et caféine, Interactions médicamenteuses)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (notice Butalbital, aspirine, caféine et codéine, Interactions médicamenteuses)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (notice Canagliflozine, Interactions médicamenteuses)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (notice Candésartan et hydrochlorothiazide, Interactions médicamenteuses)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (notice Capécitabine, Interactions médicamenteuses)

Insulin and oral hypoglycemics action may be enhanced. (notice Carvédilol, Interactions médicamenteuses)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (notice Chlorothiazide, Interactions médicamenteuses)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (notice Clarithromycine, Mises en garde et précautions)

Caution should be exercised when used with antidiabetic drugs. (notice Danazol, Interactions médicamenteuses)

…Coadministered Drug (Dose Regimen) * Dapagliflozin (Dose Regimen) * Effect on Dapagliflozin Exposure [% Change (90% CI)] C max AUC † No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10… (notice Dapagliflozine, Interactions médicamenteuses)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (notice Darunavir, Mises en garde et précautions)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (notice Darunavir et cobicistat, Mises en garde et précautions)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (notice Dexaméthasone, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. (notice Énalapril et hydrochlorothiazide, Précautions)

Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY. (notice Dulaglutide, Mises en garde et précautions)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (notice Fluoxétine, Mises en garde et précautions)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (notice Fosamprénavir, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (notice Hydrochlorothiazide, Interactions médicamenteuses)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (notice Hydrocortisone, Interactions médicamenteuses)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (notice Irbésartan et hydrochlorothiazide, Interactions médicamenteuses)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (notice Itraconazole, Interactions médicamenteuses)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (notice Kétoconazole, Interactions médicamenteuses)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (notice Lanréotide, Mises en garde et précautions)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (notice Lévofloxacine, Mises en garde et précautions)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (notice Linézolide, Mises en garde et précautions)

Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY. (notice Dulaglutide, Mises en garde et précautions)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (notice Lisinopril, Interactions médicamenteuses)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (notice Lisinopril et hydrochlorothiazide, Interactions médicamenteuses)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (notice Lopinavir et ritonavir, Mises en garde et précautions)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (notice Losartan et hydrochlorothiazide, Interactions médicamenteuses)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (notice Méthylprednisolone, Interactions médicamenteuses)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (notice Métolazone, Interactions médicamenteuses)

Antidiabetic drugs: Dosage adjustment may be required. (notice Métoprolol et hydrochlorothiazide, Interactions médicamenteuses)

Antidiabetic agents Carefully monitor blood glucose. (notice Moxifloxacine, Interactions médicamenteuses)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (notice Nadolol, Mises en garde)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (notice Naltrexone et bupropion, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (notice Octréotide, Mises en garde et précautions)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (notice Ofloxacine, Mises en garde)

• Antidiabetic drugs: Dosage adjustment may be required. (notice Olmésartan et hydrochlorothiazide, Interactions médicamenteuses)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (notice Olmésartan, amlodipine et hydrochlorothiazide, Interactions médicamenteuses)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (notice Orlistat, Mises en garde et précautions)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (notice Phentermine, Mises en garde et précautions)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (notice Pindolol, Mises en garde)

Congestive Heart Failure ACTOS, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when ACTOS is used in combination with insulin. (notice Pioglitazone, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Congestive Heart Failure Pioglitazone, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when pioglitazone is used in combination with insulin. (notice Pioglitazone et metformine, Mises en garde et précautions)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (notice Prednisolone, Interactions médicamenteuses)

Antidiabetic agents: May increase blood glucose concentrations. (notice Prednisone, Interactions médicamenteuses)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (notice Prégabaline, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (notice Rifampicine, Interactions médicamenteuses)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (notice Rifapentine, Interactions médicamenteuses)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (notice Ritonavir, Mises en garde et précautions)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (notice Salsalate, Interactions médicamenteuses)

Metformin HCl Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. (notice Saxagliptine et metformine, Mises en garde et précautions)

Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY. (notice Dulaglutide, Mises en garde et précautions)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (notice Somatropine, Mises en garde et précautions)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (notice Sotalol, Interactions médicamenteuses)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (notice Spironolactone et hydrochlorothiazide, Interactions médicamenteuses)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (notice Sulfaméthoxazole et triméthoprime, Interactions médicamenteuses)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (notice Telmisartan et hydrochlorothiazide, Interactions médicamenteuses)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (notice Temsirolimus, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Timolol, Mises en garde et précautions)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (notice Dulaglutide, Mises en garde et précautions)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (notice Trandolapril, Interactions médicamenteuses)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (notice Tranylcypromine, Mises en garde et précautions)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (notice Triamcinolone, Interactions médicamenteuses)

Dyrenium (triamterene) may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (notice Triamtérène, Interactions médicamenteuses)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (notice Triamtérène et hydrochlorothiazide, Interactions médicamenteuses)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (notice Valsartan et hydrochlorothiazide, Interactions médicamenteuses)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (notice Voriconazole, Interactions médicamenteuses)

Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY. (notice Dulaglutide, Interactions médicamenteuses)

Antidiabetic drug requirements (i.e., insulin) may be altered. (notice Amfépramone, Interactions médicamenteuses)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (notice Bupropion, Mises en garde et précautions)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (notice Clozapine, Mises en garde et précautions)

Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. (notice Dulaglutide, Mises en garde et précautions)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (notice Lovastatine, Interactions médicamenteuses)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (notice Miconazole, Interactions médicamenteuses)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (notice Moexipril, Interactions médicamenteuses)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (notice Nifédipine, Précautions)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (notice Phendimétrazine, Interactions médicamenteuses)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (notice Sulfadiazine, Interactions médicamenteuses)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (notice Telmisartan et amlodipine, Interactions médicamenteuses)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (notice Tolmétine, Interactions médicamenteuses)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (notice Ziprasidone, Mises en garde et précautions)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (notice Sulindac, Interactions médicamenteuses)